DIC-2024
- Generic Name
- DIC-2024
Dicot Pharma Initiates Phase 2a Clinical Trial of LIB-01 for Erectile Dysfunction
• Dicot Pharma has commenced its Phase 2a clinical trial to assess the efficacy of LIB-01 in treating erectile dysfunction in men.
• The double-blind, placebo-controlled study will involve 140 participants across six clinics in Sweden, Denmark, and the Netherlands.
• Participants will undergo an eight-week treatment period, with initial results expected following statistical analysis in mid-2025.
• LIB-01 aims to provide a potency agent with longer-lasting effects and fewer side effects compared to existing treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath